BE Pharmaceuticals
BE Pharmaceuticals is a privately held, early-stage U.S. manufacturer founded in 2019 in Cary, North Carolina, focused on developing sterile vaccines and injectable pharmaceutical products.
- Company typePrivate
- Founded2019
- HeadquartersCary, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What BE Pharmaceuticals does
BE Pharmaceuticals is a privately held U.S. manufacturing company founded in 2019 and headquartered in Cary, North Carolina. According to its self-description, it specializes in the development of sterile vaccines and injectable products, placing it within the contract development and manufacturing (CDMO) / specialty injectables segment of the pharmaceutical supply chain. The company operates with a very small team of 1-10 employees and is led by founder and president Bill Hill.
No products, technology platforms, regulatory filings, certifications, customer relationships, partnerships, distribution channels, or pricing models have been disclosed in the available input data. The company's website (be-pharmaceuticals.com) returned only a verification/loading page at the time of data collection, and no revenue, funding history, or operating geographies have been published. As a result, the commercial model — whether BE Pharmaceuticals acts as an in-house product developer, a CDMO serving third-party clients, or an R&D-stage startup awaiting its first regulatory milestone — cannot be determined from the available evidence.
Given the combination of micro-headcount, no disclosed capital raises, and absence of any product or customer signals in the input, the company appears to be at an early, pre-commercial or pre-revenue stage. The strategic intent — whether to pursue proprietary sterile injectable development, contract manufacturing services, or vaccine partnerships — is not articulated in the available data, and any further characterization would be speculative.
BE Pharmaceuticals firmographics
Firmographics- Name
- BE Pharmaceuticals
- Website
- https://be-pharmaceuticals.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BE Pharmaceuticals is a privately held, early-stage U.S. manufacturer founded in 2019 in Cary, North Carolina, focused on developing sterile vaccines and injectable pharmaceutical products.
- Ownership category
- akta.pro rank
BE Pharmaceuticals industry classification
Industry- Product category
- Sterile Injectable Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG), Sterile Injectable Generics (HLAIABAC)
Keywords
Where BE Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cary
- HQ country
- United States
- HQ region
- North America
Markets served
BE Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Others
BE Pharmaceuticals product offering
Product offeringCore offering
BE Pharmaceuticals is a manufacturing company that develops sterile vaccines and injectable pharmaceutical products. Based in Cary, United States, the company focuses on the development and production of sterile injectable products for the pharmaceutical industry.
Differentiator
Problem solved
Functional benefit
Products and services
- Sterile Vaccines
- Sterile Injectable Products
Companies that use BE Pharmaceuticals
Customer profileIdeal customer profiles1 record
BE Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BE Pharmaceuticals partnerships and signals
Strategic signalRecent moves1 record
BE Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Lonza: Major biopharmaceutical CDMO offering mammalian and microbial biologics manufacturing plus sterile fill-finish, directly competing for the same sterile injectable and vaccine manufacturing contracts.
- Emergent BioSolutions: Specialty biopharmaceutical company focused on vaccines and sterile injectable countermeasures for public health threats, directly aligned with BE Pharmaceuticals' sterile vaccine manufacturing focus.
- Recipharm: European-headquartered CDMO with significant sterile injectable fill-finish capacity, offering the same kind of development-to-commercial sterile injectable services BE Pharmaceuticals targets.
- Aenova: CDMO with softgel and sterile liquid/sterile injectable capabilities, serving as a mid-tier contract manufacturer comparable to where a smaller firm like BE Pharmaceuticals would compete.
- Vetter Pharma: Independent CDMO specializing in aseptic fill-finish of injectable biologics, with extensive expertise in sterile injectable development and commercial manufacturing — a tightly comparable peer for BE Pharmaceuticals' scope.
- Catalent: Global CDMO with one of the largest sterile fill-finish and injectable drug product manufacturing networks in the world, directly comparable to BE Pharmaceuticals' stated focus on sterile injectables and vaccines.
- Baxter BioPharma Solutions: Baxter's contract manufacturing arm provides sterile fill-finish and injectable manufacturing services to pharma companies, a direct operational peer in the sterile injectable CDMO space.
Broad incumbents
- Pfizer CentreOne: Pfizer's contract manufacturing arm offering sterile injectable and API manufacturing services from an established global pharma network, competing for the same outsourced sterile work.
- Seqirus: Global influenza vaccine and sterile injectable manufacturer with large-scale aseptic fill-finish operations, providing a benchmark for the scale BE Pharmaceuticals would need to reach to be a meaningful vaccine manufacturer.
- West Pharmaceutical Services: Supplier of primary packaging, containment, and delivery systems for injectable drugs, serving the same sterile injectable value chain as BE Pharmaceuticals but positioned upstream in components and devices.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
BE Pharmaceuticals social profiles
Digital presenceBE Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
BE Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
BE Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BE Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BE Pharmaceuticals
What does BE Pharmaceuticals do?
BE Pharmaceuticals is a manufacturing company that develops sterile vaccines and injectable pharmaceutical products. Based in Cary, United States, the company focuses on the development and production of sterile injectable products for the pharmaceutical industry.
Is BE Pharmaceuticals a public or private company?
BE Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BE Pharmaceuticals founded?
BE Pharmaceuticals was founded in 2019. It employs 1 to 10 people.
Where is BE Pharmaceuticals based?
BE Pharmaceuticals is headquartered in Cary, United States, in the North America region.
Who are BE Pharmaceuticals's main competitors?
Direct peers on record are Lonza, Emergent BioSolutions, Recipharm, Aenova, Vetter Pharma, Catalent and Baxter BioPharma Solutions. Broad incumbents are Pfizer CentreOne, Seqirus and West Pharmaceutical Services.
Does BE Pharmaceuticals have an API?
No public API is recorded for BE Pharmaceuticals.
What industry is BE Pharmaceuticals in?
BE Pharmaceuticals's product category is Sterile Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAAAKAB, Drug Product Fill-Finish & Aseptic Manufacturing Services. Its NAICS code is 325412 and its SIC code is 2834.